{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:17:53Z","timestamp":1769275073895,"version":"3.49.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.chest.2016.02.654","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T05:31:55Z","timestamp":1470375115000},"page":"e29-e32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells"],"prefix":"10.1016","volume":"150","author":[{"given":"Sergio","family":"Harari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Elia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Bulgheroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Provasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Moss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2016.02.654_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2213-2600(13)70090-0","article-title":"Serum VEGF-D concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial","volume":"1","author":"Young","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.chest.2016.02.654_bib2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1164\/rccm.201003-0489OC","article-title":"Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with\u00a0lymphangioleiomyomatosis","volume":"182","author":"Cai","year":"2010","journal-title":"Am\u00a0J\u00a0Respir Crit Care Med"},{"key":"10.1016\/j.chest.2016.02.654_bib3","doi-asserted-by":"crossref","first-page":"17462","DOI":"10.1073\/pnas.0407971101","article-title":"Molecular\u00a0and genetic analysis of disseminated neoplastic cells in\u00a0lymphangioleiomyomatosis","volume":"101","author":"Crooks","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.chest.2016.02.654_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/CLEP.S50780","article-title":"Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis","volume":"7","author":"Taveira-DaSilva","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.chest.2016.02.654_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1183\/13993003.00412-2015","article-title":"The changing face of a rare disease: lymphangiomyomatosis","volume":"46","author":"Harari","year":"2015","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2016.02.654_bib6","doi-asserted-by":"crossref","first-page":"6085","DOI":"10.1073\/pnas.97.11.6085","article-title":"Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis","volume":"97","author":"Carsillo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.chest.2016.02.654_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for\u00a0angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.chest.2016.02.654_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.chest.2016.02.654_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1378\/chest.13-1071","article-title":"Sirolimus decreases\u00a0circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis","volume":"145","author":"Cai","year":"2014","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.chest.2016.02.654_bib10","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-154-12-201106210-00007","article-title":"Changes\u00a0in\u00a0lung function and chylous effusions in patients with\u00a0lymphangioleiomyomatosis treated with sirolimus","volume":"154","author":"Taveira-DaSilva","year":"2011","journal-title":"Ann Intern\u00a0Med"},{"key":"10.1016\/j.chest.2016.02.654_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.12703\/P6-116","article-title":"Management of lymphangioleiomyomatosis","volume":"6","author":"Taveira-DaSilva","year":"2014","journal-title":"F1000Prime Rep"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216415242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369216415242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T07:27:42Z","timestamp":1757921262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369216415242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0012369216415242"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2016.02.654","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2016.02.654","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}